Jacobs Levy Equity Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$51M Sell
789,429
-87,528
-10% -$6.17M 0.21% 115
2025
Q4
$59M Sell
876,957
-21,235
-2% -$1.43M 0.23% 102
2025
Q3
$65.9M Sell
898,192
-104,427
-10% -$6.94M 0.26% 89
2025
Q2
$52.2M Buy
1,002,619
+820,265
+450% +$46.7M 0.2% 112
2025
Q1
$11.6M Buy
+182,354
New +$10.6M 0.05% 312
2020
Q2
Sell
-198,772
Closed -$3.58M 1083
2020
Q1
$3.58M Buy
198,772
+21,250
+12% +$403K 0.05% 359
2019
Q4
$3.15M Sell
177,522
-311,480
-64% -$5.39M 0.03% 459
2019
Q3
$7.58M Sell
489,002
-40,596
-8% -$669K 0.09% 260
2019
Q2
$9.1M Buy
529,598
+68,420
+15% +$1.1M 0.13% 207
2019
Q1
$7.42M Buy
461,178
+133,700
+41% +$2.17M 0.11% 257
2018
Q4
$4.79M Sell
327,478
-23,500
-7% -$375K 0.08% 272
2018
Q3
$6.38M Buy
350,978
+38,348
+12% +$672K 0.09% 263
2018
Q2
$5.27M Buy
312,630
+57,890
+23% +$1.09M 0.08% 294
2018
Q1
$4.99M Buy
254,740
+182,630
+253% +$3.54M 0.08% 284
2017
Q4
$1.46M Buy
72,110
+35,800
+99% +$658K 0.03% 533
2017
Q3
$631K Buy
+36,310
New +$492K 0.01% 669
2017
Q1
Sell
-48,482
Closed -$479K 949
2016
Q4
$479K Buy
+48,482
New +$531K 0.01% 683
2016
Q3
Sell
-19,100
Closed -$165K 1060
2016
Q2
$165K Buy
19,100
+500
+3% +$4.93K ﹤0.01% 1039
2016
Q1
$176K Buy
+18,600
New +$175K ﹤0.01% 985
2015
Q4
Sell
-12,700
Closed -$171K 843
2015
Q3
$171K Sell
12,700
-1,800
-12% -$36.1K ﹤0.01% 723
2015
Q2
$327K Buy
+14,500
New +$255K 0.01% 635

Other funds holding HALO

Jacobs Levy Equity Management's HALO Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Halozyme (HALO) stake by 10% in Q1 2026, selling an estimated $6.17M and leaving 789,429 shares worth $51M. The position accounts for 0.21% of the portfolio, ranked #115.

Jacobs Levy Equity Management first reported a position in HALO in Q2 2015 and has held it in 21 quarters since. The position peaked at $65.9M in Q3 2025. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Jacobs Levy Equity Management held 789,429 shares of Halozyme worth $51M as of Q1 2026.
  • Jacobs Levy Equity Management sold 87,528 Halozyme shares in Q1 2026, an estimated $6.17M.
  • Halozyme made up 0.21% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #115 holding.
  • Jacobs Levy Equity Management first reported a position in Halozyme in Q2 2015 and has held it in 21 quarters since.
  • Jacobs Levy Equity Management's Halozyme position peaked at $65.9M in Q3 2025.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.